Shared Decision Making (SDM)

Impact of SDM on patients, and determining opportunities to improve SDM

MS-SUPPORT OUTCOME STUDIES TRUVEN TREATMENT IN MS ANALYSIS

MS-SUPPORT Randomized Controlled Study

This study aims to validate the shared decision-making tool, MS-SUPPORT, in a sample of US adults with relapsing forms of MS and their HCPs. The study will assess: DMT utilization, patient-provider communication, DMT adherence, quality of decision making, quality of care, quality of life, decision conflict, and perception of illness

Partner: Col, Shared Decision Making Resources

Status: Complete

MS-SUPPORT Randomized Controlled Study Description pdf (492.3 kB)

View

Poster presented at CMSC 2021 pdf (256.3 kB)

View

Poster presented at CMSC 2022 pdf (1.8 MB)

View

Manuscript doi:https://doi.org/10.1016/j.msard.2023.105092

Col NF, Solomon AJ, Alvarez E, et al. Implementing shared decision-making for multiple sclerosis: The MS-SUPPORT Tool. Mult Scler Relat Disord. 2023;80. doi:10.1016/j.msard.2023.105092

Outcomes Study

This study is a multi-center observational real-world platform which aims to integrate data from multiple sources to facilitate patient and provider engagement, shared decision making, and participation in high-priority research questions, as well as identify a core set of patient reported outcomes (PROs) that correlates with disease progression and activity

Partner: Tornatore, MedStar Georgetown; English, MS Center of Atlanta

Status: Ongoing

Outcomes Study Description pdf (734.1 kB)

View

Outcomes Study Infographic pdf (2.6 MB)

View

Poster presented at AAN 2023 pdf (788.3 kB)

View

Poster presented at ECTRIMS 2023 png (1.4 MB)

View

Truven Treatment in MS Analysis

Evaluate disease progression and health resource utilization (HRU) in people with MS (PwMS) treated with a disease modifying treatment (DMT): adherent users versus non-adherent users over 6 years

Partner: Amezcua, USC; Williams, Joi Wellness

Status: Complete

Poster presented at CMSC 2020 pdf (2.6 MB)

View

Manuscript doi: 10.1016/j.msard.2023.104866

Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data. Mult Scler Relat Disord. 2023;77. doi:10.1016/j.msard.2023.104866

Welcome to MS-LINK(TM) Research

Help us direct you to the right information by selecting one of the following options:

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website.